Journal articles on the topic 'E.B. Moore and Co'
To see the other types of publications on this topic, follow the link: E.B. Moore and Co.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'E.B. Moore and Co.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
BURGIN, K. "Realities in childbearing, second edition By Mary Lou Moore, , and Ora Strickland, . Philadelphia: W. B. Saunders Co., 1983. 1126 pages. $29.50, hardcover." Journal of Nurse-Midwifery 30, no. 2 (March 1985): 129. http://dx.doi.org/10.1016/0091-2182(85)90129-6.
Full text
2
KITLV, Redactie. "Book Reviews." New West Indian Guide / Nieuwe West-Indische Gids 62, no. 1-2 (January 1, 1988): 51–101. http://dx.doi.org/10.1163/13822373-90002046.
Full textAbstract:
-Brenda Plummer, Carol S. Holzberg, Minorities and power in a black society: the Jewish community of Jamaica. Maryland: The North-South Publishing Company, Inc., 1987. xxx + 259 pp.-Scott Guggenheim, Nina S. de Friedemann ,De sol a sol: genesis, transformacion, y presencia de los negros en Colombia. Bogota: Planeta Columbiana Editorial, 1986. 47 1pp., Jaime Arocha (eds)-Brian L. Moore, Mary Noel Menezes, Scenes from the history of the Portuguese in Guyana. London: Sister M.N. Menezes, RSM, 1986. vii + 175 PP.-Charles Rutheiser, Brian L. Moore, Race, power, and social segmentation in colonial society: Guyana after slavery 1838-1891. New York; Gordon and Breach, 1987. 310 pp.-Thomas Fiehrer, Virginia R. Dominguez, White by definition: social classification in Creole Louisiana. Rutgers, New Jersey: Rutgers University Press, 1986. xviii + 325 pp.-Kenneth Lunn, Brian D. Jacobs, Black politics and urban crisis in Britain. Cambridge, London, New Rochelle, Melbourne and Sydney: Cambridge University Press, 1986. vii + 227 pp.-Brian D. Jacobs, Kenneth Lunn, Race and labour in twentieth-cenruty Britain, London: Frank Cass and Co. Ltd., 1985. 186 pp.-Kenneth M. Bilby, Dick Hebdige, Cut 'n' mix: culture, identity and Caribbean Music. New York: Metheun and Co. Ltd, 1987. 177 pp.-Riva Berleant-Schiller, Robert Dirks, The black saturnalia: conflict and its ritual expression on British West Indian slave plantations. Gainesville, Fl.: University of Florida Press, Monographs in Social Sciences No. 72. xvii + 228.-Marilyn Silverman, James Howe, The Kuna gathering: contemporary village politics in Panama. Austin, Texas: University of Texas Press, 1986. xvi + 326 pp.-Paget Henry, Evelyne Huber Stephens ,Democratic socialism in Jamaica: the political movement and social transformation in dependent capitalism. Princeton, N.J.: Princeton University Press, 1985. xx + 423 pp., John D. Stephens (eds)-Bridget Brereton, Scott B. Macdonald, Trinidad and Tobago: democracy and development in the Caribbean. New York, Connecticut, London: Praeger Publishers, 1986. ix + 213 pp.-Brian L. Moore, Kempe Ronald Hope, Guyana: politics and development in an emergent socialist state. Oakville, New York, London: Mosaic Press, 1985, 136 pp.-Roland I. Perusse, Richard J. Bloomfield, Puerto Rico: the search for a national policy. Boulder and London: Westview Press, Westview Special Studies on Latin America and the Caribbean, 1985. x + 192 pp.-Charles Gilman, Manfred Gorlach ,Focus on the Caribbean. 1986. Amsterdam/Philadelphia, John Benjamins., John A. Holm (eds)-Viranjini Munasinghe, EPICA, The Caribbean: survival, struggle and sovereignty. Washington, EPICA (Ecumenical Program for Interamerican Communication and Action), 1985.-B.W. Higman, Sidney W. Mintz, Sweetness and power: the place of sugar in modern history. New York: Elisabeth Sifton Books, Viking Penguin Inc., 1985. xxx + 274 pp.
3
Thadhani, N. N. "Review of: “ CHEMICAL METALLURGY ” by J.J. Moore Co-authors: E.A. Boyce, MJ. Brooks, B. Perry, P.J. Sheridan Butterworths and Co. (Publishers) London, Second Edition, 435 pages, hard cover, 1990." Materials and Manufacturing Processes 7, no. 4 (January 1992): 671–73. http://dx.doi.org/10.1080/10426919208947449.
Full text
4
Horrocks, M. "Endovascular surgery. W. S. Moore and S. S. Ahn, eds. 190 × 266 mm. Pp. 550. Illustrated. 1989. London: W. B. Saunders and Co. £64.00 hardhack." British Journal of Surgery 77, no. 10 (October 1990): 1197. http://dx.doi.org/10.1002/bjs.1800771049.
Full text
5
Pautler, Paul A. "BOOK REVIEW: CURB RIGHTS: A FOUNDATION FOR FREE ENTERPRISE IN URBAN TRANSIT, by Klein, D. B., Moore, A. T. and Reja, B., Washington, DC: Brookings Institution Press, 1997, 148 pp." Managerial and Decision Economics 18, no. 4 (June 1997): 345–46. http://dx.doi.org/10.1002/(sici)1099-1468(199706)18:4<345::aid-mde830>3.0.co;2-k.
Full text
6
Shrestha, D. B., P. Budhathoki, Y. R. Sedhai, L. B. Shrestha, S. Awal, B. Upadhaya Regmi, J. Yadav, R. Baniya, S. Thapaliya, and G. Dangal. "Prevalence of Hepatitis B and C among HIV Infected Patients in Nepal over 1990-2020." Kathmandu University Medical Journal 19, no. 1 (March 31, 2021): 132–39. http://dx.doi.org/10.3126/kumj.v19i1.49598.
Full textAbstract:
Background Hepatitis B and C (HBV and HCV) are viral infections caused by corresponding viruses. Here in this study we planned to conduct this meta-analysis to pool data on the prevalence and risk factors of HBV and/or HCV among HIV patients in Nepal.
Method We used MOOSE guideline for the systemic review of available literature. We searched online databases using appropriate keywords. We used CMA-3 for data synthesis. Odds ratio, and proportion were used to estimate the outcome with a 95% confidence interval where appropriate. We assessed the heterogeneity using the I-squared (I2) test.
Result We included nine studies for our synthesis. Pooling of data showed HBV in 4.6% (CI: 3.7-5.6), HCV in 19.7% (CI: 10.8-33.0), both HBV and HCV in 1.3% (CI: 0.5-3.7) in HIV affected individuals. Among HBV co-infected HIV positive patients, 59.5% (CI: 25.5-86.3) were male; 76.1% (CI: 30.1-96.0) were married and 43.6% (CI: 3.8-93.8) had a history of intravenous drug use (IVDU). Among HCV co-infected HIV positive individuals 88.3% (CI: 73.6-95.4) were male; 63.6% (CI: 55.4-71.1) were married; 91.5% (CI: 68.6-98.1) were literate; 59.2% (CI: 49.9-67.9) were on ART; and 92.2% (95%CI: 84.9-96.1) had a history of IVDU.
Conclusion The pooled prevalence of co-infection with HBV, HCV, and combined HBV and HCV were 4.6%, 19.7% and 1.3% respectively among HIV positive patients. Thus, it is necessary to appropriately screen for HBV and HCV in individuals diagnosed with HIV and high-risk populations. IVDU remains the most common risk factor found in co-infected individuals.
7
Krishnan, Venkatesh, Ching-Wei Chang, Habib Hamidi, Michael A. Bookman, Charles Landen, Tashanna Myers, Hiroaki Kajiyama, et al. "Abstract 5702: Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5702. http://dx.doi.org/10.1158/1538-7445.am2023-5702.
Full textAbstract:
Abstract Background: Tumor biomarkers such as CD8 density and location (i.e., immune inflamed phenotype) and immune rich molecular subtype have been linked to immune checkpoint blockade (ICB) overall survival (OS) in different cancers. The IMagyn050 trial (NCT03038100), which evaluated the efficacy of Atezo vs placebo (Pla) with carboplatin, paclitaxel and bevacizumab (CPB) in front line ovarian cancer patient (pts), did not meet its co-primary endpoints of PFS in ITT or PD-L1+ (Moore et al. JCO 2021). In the current IMagyn050 substudy we assessed potential predictive tumor immune biomarkers for Atezo clinical benefit. Methods: FFPE tumors from the biomarker evaluable population were tested for PD-L1 IHC, CD8/PanCK IHC (total CD8 T cells and immune location phenotypes [inflamed, excluded, desert]) and RNA-seq (to derive molecular subtypes, biological pathways and cellular components [xCELL]) in tissue from baseline (n=860), on-treatment (OT, 9 weeks, n=233), intra- (n=8) and inter-lesion (n=12) matched samples. Hazard ratio (HR) interaction test from multivariate adjusted Cox-regression analysis for PFS and OS was performed to test predictive biomarkers. Results: While tumors with CD8 T cells, immunoreactive molecular subtypes or immune inflamed phenotype were enriched for PD-L1+, only pts with immune inflamed tumors showed improved OS Atezo benefit (HR 0.67). Improved Atezo PFS/OS benefit was also observed in pts with whose tumors had high oxidative phosphorylation (OXPHOS, HR: 0.72/0.65) and UV Response (UV, HR: 0.64/0.58) but not IFNγ response. Plasma B cells were linked to improved OS Atezo benefit vs Pla (HR 0.53). We leveraged OT samples from pts in the neoadjuvant cohort to assess treatment effect on the tumor microenvironment. Analyses showed that CPB reduced tumor proliferation and increased tumor immune inflammation (CD8 T cells, PD-L1 and IFNα/IFNγ response), further increased by Atezo. Immune inflammation is challenging in ovarian cancer due to extensive tumor heterogeneity. Prevalence of tumor biomarkers varied by anatomic locations: total CD8, CD8 localization and molecular subtypes. Inter- and intra-lesion biomarker status within the same pt showed PD-L1 and plasma B cells as most consistent. Molecular subtypes and immune phenotypes had moderate intra-lesion agreement but discordant between lesions. PD-L1 and OXPHOS were the only biomarkers linked to Atezo benefit regardless of anatomical location. Conclusion: This comprehensive exploratory study suggests that DNA damage, OXPHOS, plasma B cells and immune inflamed tumors, but not molecular subtypes or total CD8 T cells, may predict Atezo + CPB OS. This treatment promotes immune inflammation in OC tumors. Notably, we found that several biomarkers are highly heterogeneous. Our findings highlight the challenges of achieving durable clinical benefit from targeted immunotherapy in ovarian cancer pts. Citation Format: Venkatesh Krishnan, Ching-Wei Chang, Habib Hamidi, Michael A. Bookman, Charles Landen, Tashanna Myers, Hiroaki Kajiyama, Sakari Hietanen, Lyndsay Willmott, Premal Thaker, Cagatay Taskiran, Jalid Sehouli, Victor Khor, Yvonne Lin Liu, Sandro Pignata, Kathleen Moore, Luciana Molinero. Ovarian cancer tumor microenvironment and atezolizumab (atezo) clinical activity: IMagyn050 sub-study. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5702.
8
Morrison, James C., Kimlin T. Ashing, Gaole Song, Timethia J. Bonner, Che Ngufor, Getachew Dagne, Arnold Merriweather, et al. "Abstract 808: iCCaRE engagement of faith-based organizations to co-create and co-disseminate infographics addressing disparities in prostate cancer literacy and clinical and biospecimen studies." Cancer Research 84, no. 6_Supplement (March 22, 2024): 808. http://dx.doi.org/10.1158/1538-7445.am2024-808.
Full textAbstract:
Abstract Black men hold the highest prostate cancer burden among all ethnicities; thus, there is an urgent need for research to inform the development and implementation of a culturally tailored intervention to reduce disparities and improve outcomes. In response, the Inclusive Cancer Care Research Equity (iCCaRE) Consortium was created to advance health equity and reduce disparities in prostate cancer. Addressing the unique needs of Black men require a genuine bidirectional relationship between scientist and the community. In the Black community, faith-based organizations are respected institutions advocating for health equity and justice. Given their vital role as community health gatekeepers, the iCCaRE Consortium partners with faith-based organizations. Rooted in community engaged research (CER), we conducted an environmental scan through stakeholder meetings to discuss the prevailing challenges and opportunities to meet the needs of the Black community along the prostate cancer care continuum. iCCaRE investigators including Partnership Engagement Services (PES) core partnered with faith-based organizations to ensure and advance community responsive cancer prevention. Together, with our faith-based leaders (N=18), we identified gaps including issues associated with the care continuum from screening to diagnosis and from treatment to survivorship; disparities according to health coverage and social determinants of health, and best practices to assist patients including care coordination, patient navigation, digital innovations, and programs offered by patient advocacy organizations. In response to the needs of the community and the strengths of faith-based organization, we prioritized our initial focus on increasing community prostate cancer literacy and activation using co-design educational infographics for both traditional and technology-based communication platforms. The infographics provided evidence-based facts about prostate cancer burden in the Black community; and using a call to action approach, we emphasized the importance of taking action for life saving screening, prevention and healthy lifestyle. Taking action in prostate cancer symptom recognition, survivorship care, and quality care. Also, co-designed infographics were created for clinical studies and biospecimen awareness and participation and the importance of advocacy and equitable care. Another component incorporated face to face trainings and presentations to enhance their knowledge of cancer screening tools, epidemiology of prostate cancer, and pathways to care. This presentation highlighted the first step towards community based intervention development, implementation and dissemination towards equity and justice for prostate cancer prevention and patient/survivor improvements for Black men. Citation Format: James C. Morrison, Kimlin T. Ashing, Gaole Song, Timethia J. Bonner, Che Ngufor, Getachew Dagne, Arnold Merriweather, John McCall, Ewan Cobran, Cassandra N. Moore, Fornati Bedell, Rotimi Oladapo, Floyd B. Willis, Runcie Chidebe Chidebe, Noreen A. Stephenson, JoAnne S. Oliver, Vinessa Gordon, Folakemi Odedina. iCCaRE engagement of faith-based organizations to co-create and co-disseminate infographics addressing disparities in prostate cancer literacy and clinical and biospecimen studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 808.
9
Moore, Colin Edward, and Elod L. Gyenge. "Tuning the Composition of Bimetallic Electrodeposited Sn-Pb Catalysts for Enhanced Activity and Durability in CO2 Electroreduction to Formate." ECS Meeting Abstracts MA2018-01, no. 31 (April 13, 2018): 1829. http://dx.doi.org/10.1149/ma2018-01/31/1829.
Full textAbstract:
Efficient and durable catalysts are needed to convert CO2 to value added products. In recent years, extensive research has been done on tin (Sn) because of its high faradaic efficiency for producing formate (HCOO-) from CO2 [1–5] and lead (Pb) because of its high hydrogen evolution (HER) overpotential [4, 6]. In our recent study [7], bimetallic Sn-Pb catalysts with five different Sn/Pb atomic ratios were electrodeposited on Teflonated carbon paper and non-Teflonated carbon cloth using both metal fluoroborate- and metal oxide-containing deposition media to produce catalysts for electrochemical reduction of CO2 (ERC) to HCOO-. The interaction between catalyst composition, morphology, substrate and deposition media was investigated by cyclic voltammetry followed by chronoamperometry at -2.0 V vs. Ag/AgCl for 2 h in 0.5 M KHCO3. Sn majority catalysts with 15 to 35 atomic % Pb generated faradaic efficiencies up to 95% with stable performance. Pure Sn catalysts on the other hand, in spite of high initial stage formate production rates, experienced extensive (up to 30%) decrease of the faradaic efficiency. The decrease in faradaic efficiency is most likely due to the reduction of the SnO2 layer to metallic Sn0 during formate production. This newly formed Sn0 surface is no longer active for CO2 reduction to formate but instead preferentially produces parasitic H2. XRD results demonstrated the presence of polycrystalline SnO2 after electrolysis using Sn-Pb catalysts with 35 atomic % Pb and its absence in case of pure Sn. It is proposed that the presence of Pb (15 to 35 at %) in Sn majority catalysts stabilized SnO2, which is responsible for the enhanced faradaic efficiency and catalytic durability in ERC. Our results point to a promising strategy for increasing the durability of Sn based catalyst materials for ERC. Oloman C, Li H (2008) Electrochemical Processing of Carbon Dioxide. ChemSusChem 1:385–391. doi: 10.1002/cssc.200800015 Li H, Oloman C (2005) The Electro-Reduction of Carbon Dioxide in a Continuous Reactor. J Appl Electrochem 35:955–965. doi: 10.1007/s10800-005-7173-4 Bumroongsakulsawat P, Kelsall GH (2015) Tinned graphite felt cathodes for scale-up of electrochemical reduction of aqueous CO2. Electrochimica Acta 159:242–251. doi: 10.1016/j.electacta.2015.01.209 Alvarez-Guerra M, Del Castillo A, Irabien A (2014) Continuous electrochemical reduction of carbon dioxide into formate using a tin cathode: Comparison with lead cathode. Chem Eng Res Des 92:692–701. doi: 10.1016/j.cherd.2013.11.002 Chen Y, Kanan MW (2012) Tin Oxide Dependence of the CO2 Reduction Efficiency on Tin Electrodes and Enhanced Activity for Tin/Tin Oxide Thin-Film Catalysts. J Am Chem Soc 134:1986–1989. doi: 10.1021/ja2108799 Innocent B, Liaigre D, Pasquier D, Ropital F, Léger J-M, Kokoh KB (2009) Electro-reduction of carbon dioxide to formate on lead electrode in aqueous medium. J Appl Electrochem 39:227–232. doi: 10.1007/s10800-008-9658-4 Gyenge EL, Moore CE (2017) Tuning the Composition of Bimetallic Electrodeposited Sn-Pb Catalysts for Enhanced Activity and Durability in CO2 Electroreduction to Formate. ChemSusChem 17:3512-3519 . doi: 10.1002/cssc.201700761 Figure 1. Cumulative formate production faradaic efficiency (FE) (a, c) and total moles of formate synthesized (b, d) for catalysts produced by electrodeposition using the fluoroborate bath. Chronoamperometry at -2.0 V vs Ag/AgCl in 0.5 M KHCO3 at 293 K for 2 hours. Substrates: (a, b) teflonated carbon paper and (c, d) carbon cloth. Figure 1
10
Moore, Jay A., Andrew M. Evens, Justin Newberg, Eric A. Severson, Jennifer Mills, Jordan Carter, Rahul Matnani, Jo-Anne Vergilio, Sally E. Trabucco, and Shridar Ganesan. "Genomic Ancestry in B Cell Lymphoid Malignancies." Blood 136, Supplement 1 (November 5, 2020): 5–6. http://dx.doi.org/10.1182/blood-2020-137533.
Full textAbstract:
Introduction: B cell lymphoma/leukemias (BCL) are a diverse set of malignancies. The genomic landscape of many BCL subtypes have been described. However, genomic ancestry has rarely been investigated. We applied SNP-based genomic ancestry prediction to comprehensive genomic profiling (CGP) data to identify significant enrichment of ancestry by subtype. We also explored enrichment of genomic alterations (GAs) by ancestry. Methods: During routine clinical care, 2834 unique patient (pt) samples of BCLs underwent CGP for 406 DNA genes and 265 RNA genes to detect all classes of GAs on the FoundationOne® Heme platform. This dataset was enriched for relapsed/refractory pts as they are more likely to have genomic testing as part of clinical care (referral bias). Each pt was assigned an ancestry of American (AMR), African (AFR), East Asian (EAS), European (EUR), or South Asian (SAS) using a SNP-based machine learning methodology (J. Newberg et al., AACR 2019). AMR was defined using a mix of Hispanic and Latin American populations. Enrichment analyses were performed using Fisher's exact test with FDR correction. Results: We compared the ancestry composition of each BCL subtype to the overall ancestry composition of the rest of the sample set (Fig 1A). Pts of AFR ancestry were overrepresented in plasmablastic lymphoma (PBL) (OR=7.2, P<0.05); EAS pts were overrepresented in Burkitt lymphoma (BL) (OR=4.99, P<0.05); and AMR pts were overrepresented in acute B-cell lymphoblastic leukemia/lymphoma (B-ALL) (OR=3.2, P<0.001). AMR SNPs have been associated with increased risk of B-ALL and worse prognosis (PMID: 21297632). We also investigated GAs enriched in specific ancestries. B-ALL AMR pts were enriched for GAs in IL7R, IGH, CRLF2, JAK2, and IKZF1 compared to other ancestries in B-ALL (Fig 1B). These genes were associated with the high-risk Philadelphia chromosome-like ALL (Ph-like ALL) molecular subtype of B-ALL (PMID: 30181314). We found 33% of all B-ALL contained GAs consistent with Ph-like ALL (PMID: 30181314). While we noted enrichment of AMR pts in the overall B-ALL cohort, we identified additional enrichment in the Ph-like B-ALL cohort with 47% of Ph-like B-ALL pts being of AMR ancestry (OR=1.85, p<0.001). AMR pts accounted for almost half the Ph-ALL pts in this cohort; however, even in B-ALL pts without Ph-like genomic features, 32% were of AMR ancestry suggesting this enrichment is not simply due to increased CGP testing in Ph-ALL. In diffuse large B cell lymphoma (DLBCL), we found pts to be primarily of EUR ancestry, however we identified ancestry bias in GAs (Fig 1C). CD79B alterations were enriched in DLBCL pts of SAS ancestry, although not significant after FDR correction, consistent with previous reports of increased Activate B-Cell (ABC) cell of origin (COO) subtype and BTK signaling in pts from South East Asia (PMID: 31189540). CDKN2A, also frequently altered in ABC COO subtype, trended towards enrichment in EAS ancestry. CUX1, a tumor suppressor involved in PI3K signaling, was strongly enriched in AFR pts in both DLBCL and B-ALL. One CUX1 insertion variant (G870_G871insSGG) was particularly common in AFR pts with BCL (7/9 AFR, 2/9 AMR), which has been reported previously in Myelodysplastic syndromes (PMID: 24030381). CUX1 alterations have been reported to be associated with increased PI3K signaling suggesting in part PI3K inhibitor trials should proactively include pts of AFR ancestry (PMID: 24316979). Finally, EZH2 alterations were slightly enriched in AMR DLBCL pts, but showed no ancestry bias in follicular lymphoma (FL) pts, of interest given the recent EZH2 inhibitor approval in FL. Conclusions: This study described multiple important genomic differences in BCL using genomic ancestry rather than patient-reported descriptive variables. Enrichment of AMR ancestry was observed in B-ALL overall, and in Ph-like B-ALL. In addition, enrichment of CUX1 alterations was observed in both DLBCL and B-ALL of AFR ancestry. While precision medicine holds the promise to advance cancer care, many acknowledge the potential to unintentionally deepen existing health disparities (PMID: 31112478). Further analysis of ancestry informative markers in BCL, including enrichment of ancestry markers in specific cancer subtypes and ancestry-associated enrichment of specific GAs, may lead to insights into cancer biology and contribute to ongoing cancer health disparities research. Disclosures Moore: Foundation Medicine, Inc: Current Employment; Roche Holdings: Current equity holder in publicly-traded company. Evens:Abbvie: Consultancy, Honoraria; Mylteni: Consultancy, Honoraria; Research To Practice: Honoraria, Speakers Bureau; MorphoSys: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria; Merck: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding. Newberg:Roche Holdings: Current equity holder in publicly-traded company; Foundation Medicine, Inc: Current Employment. Severson:Foundation Medicine, Inc: Current Employment; Roche Holdings: Current equity holder in publicly-traded company. Mills:Foundation Medicine, Inc: Current Employment; Abbvie: Current equity holder in publicly-traded company; Roche Holdings: Current equity holder in publicly-traded company; Abbott: Current equity holder in publicly-traded company; Merck: Current equity holder in publicly-traded company. Vergilio:Roche Holdings: Current equity holder in publicly-traded company; Foundation Medicine, Inc: Current Employment. Trabucco:F. Hoffmann-La Roche, Bristol-Myers Squibb Co., BioNTech: Current equity holder in publicly-traded company; Patent pending with Foundation Medicine and Genentech: Patents & Royalties: Patent pending; Foundation Medicine, Inc.: Current Employment; Bristol-Myers Squibb Co: Current equity holder in publicly-traded company; BioNTech: Current equity holder in publicly-traded company; Loxo Oncology: Divested equity in a private or publicly-traded company in the past 24 months. Ganesan:M2GEN: Research Funding; Foundation Medicine, Inc: Consultancy; Inspirata: Consultancy; Merck: Consultancy, Current Employment, Current equity holder in publicly-traded company; Silagene: Consultancy; Foghorn Therapeutics: Consultancy; Roche: Consultancy; Novartis: Consultancy.
11
Bragg, Hope A. "Michigan's State Forests: a Century of Stewardship William B Botti, Michael D. Moore . Michigan's State Forests: a Century of Stewardship. Michigan State University Press. East, Lansing, MI. 201 paperback. 2006. ISBN: 0-87013-780-8." Natural Areas Journal 28, no. 3 (October 2008): 321–22. http://dx.doi.org/10.3375/0885-8608(2008)28[321:msfaco]2.0.co;2.
Full text
12
Hueper, K. "Optimization and Dynamical Systems by U. Helmke and J. B. Moore with a Foreword by R. W. Brockett, Springer-Verlag, London, 1996. ISBN 3-540-19857-1, xiii+403 pp., Price £55.00." International Journal of Adaptive Control and Signal Processing 13, no. 4 (June 1999): 322–23. http://dx.doi.org/10.1002/(sici)1099-1115(199906)13:4<322::aid-acs539>3.0.co;2-d.
Full text
13
Livingtson, Katherine. "The Art of Geology . Eldridge M. Moores and F. Michael Wahl, Eds. Geological Society of America, Boulder, CO, 1988. viii, 140 pp., illus. $37.50. GSA Special Paper no. 225." Science 243, no. 4892 (February 10, 1989): 826. http://dx.doi.org/10.1126/science.243.4892.826.b.
Full text
14
Scott, John D., Kerry L. Clark, Nikki M. Coble, and Taylor R. Ballantyne. "Detection and Transstadial Passage of Babesia Species and Borrelia burgdorferi Sensu Lato in Ticks Collected from Avian and Mammalian Hosts in Canada." Healthcare 7, no. 4 (December 2, 2019): 155. http://dx.doi.org/10.3390/healthcare7040155.
Full textAbstract:
Lyme disease and human babesiosis are the most common tick-borne zoonoses in the Temperate Zone of North America. The number of infected patients has continued to rise globally, and these zoonoses pose a major healthcare threat. This tick-host-pathogen study was conducted to test for infectious microbes associated with Lyme disease and human babesiosis in Canada. Using the flagellin (flaB) gene, three members of the Borrelia burgdorferi sensu lato (Bbsl) complex were detected, namely a Borrelia lanei-like spirochete, Borrelia burgdorferi sensu stricto (Bbss), and a distinct strain that may represent a separate Bbsl genospecies. This novel Bbsl strain was detected in a mouse tick, Ixodes muris, collected from a House Wren, Troglodytes aedon, in Quebec during the southward fall migration. The presence of Bbsl in bird-feeding larvae of I. muris suggests reservoir competency in three passerines (i.e., Common Yellowthroat, House Wren, Magnolia Warbler). Based on the 18S ribosomal RNA (rRNA) gene, three Babesia species (i.e., Babesia divergens-like, Babesia microti, Babesia odocoilei) were detected in field-collected ticks. Not only was B. odocoilei found in songbird-derived ticks, this piroplasm was apparent in adult questing blacklegged ticks, Ixodes scapularis, in southern Canada. By allowing live, engorged ticks to molt, we confirm the transstadial passage of Bbsl in I. muris and B. odocoilei in I. scapularis. Bbss and Babesia microti were detected concurrently in a groundhog tick, Ixodes cookei, in Western Ontario. In Alberta, a winter tick, Dermacentor albipictus, which was collected from a moose, Alces alces, tested positive for Bbss. Notably, a B. divergens-like piroplasm was detected in a rabbit tick, Haemaphysalis leporispalustris, collected from an eastern cottontail in southern Manitoba; this Babesia species is a first-time discovery in Canada. This rabbit tick was also co-infected with Borrelia lanei-like spirochetes, which constitutes a first in Canada. Overall, five ticks were concurrently infected with Babesia and Bbsl pathogens and, after the molt, could potentially co-infect humans. Notably, we provide the first authentic report of I. scapularis ticks co-infected with Bbsl and B. odocoilei in Canada. The full extent of infectious microorganisms transmitted to humans by ticks is not fully elucidated, and clinicians need to be aware of the complexity of these tick-transmitted enzootic agents on human health. Diagnosis and treatment must be administered by those with accredited medical training in tick-borne zoonosis.
15
Shieh, Jae Hung, Peter G. Steinherz, Jason Shieh, and Malcolm A. S. Moore. "In Vitro Culture Reveals Microenvironment-Dependent Growth, Heterogeneity and Hierarchical Structure of Primary Human Pediatric Pre-B Cell Acute Lymphoblastic Leukemia (pre-B ALL) Cells." Blood 118, no. 21 (November 18, 2011): 1483. http://dx.doi.org/10.1182/blood.v118.21.1483.1483.
Full textAbstract:
Abstract Abstract 1483 In Vitro culture reveals microenvironment-dependent growth, heterogeneity and hierarchical structure of primary human pediatric pre-B cell acute lymphoblastic leukemia (pre-B ALL) cells. J.-H. Shieh1, P. Steinherz2, J Shieh3 and M. A.S. Moore1. 1Moore Laboratory. Cell Biology Program and 2Leukemia and Lymphoma Studies, Department of Pediatrics, Memorial-Sloan Kettering Cancer Center, New York, NY. 3Department of Biology, Brandeis Univ., Waltham, MA Pre-B cell acute lymphoblastic leukemia (pre-B ALL) is the most common leukemia in children. Although this pediatric pre-B ALLs are treatable, no in vitro nor in vivo models are available to investigate their pathophysiology other than a number of established cell lines that grow in the absence of any cytokine dependence or stromal interaction. To address this issue, we systemically evaluated the effects of various tissue culture parameters to the growth of primary pre-B ALL cells. A serum-free MS-5 cells (a murine bone marrow stromal cell line) co-culture system is capable of expanding the pre-B ALL CD34+CD19+ cells and supporting their differentiation to CD34−CD19+ B cells. This expansion requires a contact between the stromal cells and the pre-B ALL cells, and is inhibited by fetal bovine serum and IL-6 in a dose-dependent manner. c-Kit ligand and Flt3 ligand can reverse the IL-6 inhibition. Expansion of individual CD34+CD19+ cells revealed a hierarchical structure with respect to CD34 antigen expression and an heterogeneity in cell proliferation. When the pre-B ALL cells were sorted into CD34dim and CD34bright populations, the CD34dim cells were capable of a faster proliferation but gradually lost their CD34 antigen. In contrast, the CD34bright cells were more slowly proliferating and retained their CD34 antigen. We transduced the B-ALL cells with a fusion gene expressing green fluorescent protein (GFP) and luciferase (GFP-Lu-pre-B ALL). These GFP-Lu-pre-B ALL cells display the similar in vitro characteristics and in vivo xenograftment to NOD/SCID IL2R gamma null (NSG) mice as the non-transduced pre-B ALL cells. One hundred, 103, 104 or 105 GFP-LU-pre-B ALL CD34+ cells were i.v. transplanted to NSG mice. Both 104 and 105 cells resulted in the engraftment of the leukemia cells in limbs and cranium as judged by imaging after 6 weeks, and 103 cells engrafted after 13 weeks. When the 105 cells-transplanted mice were sacrificed after 14 weeks, the harvested peripheral blood, spleen (3–4×108cells/spleen) and bone marrow (5−10×106 cells/femur) displayed 2–3%, 51–55% and 75–81% of human CD34+CD19+ cells, respectively. Human CD34−CD19+ cells were 1–2%, 12–13% and 15–21%, respectively. Therefore, our stromal culture system supports leukemic stem cell/leukemia initiating cell proliferation and closely recapitulates the growth of primary human pre-B ALL cells in their niche in vivo, and reveals the heterogeneity and hierarchical structure of human pre-B ALL cells. The in vitro stromal co-culture system combined with the xenograft model of GFP-Lu-pre-B ALL cells provides powerful tools to dissect the pathophysiology of human pre-B ALL, and to screen new drugs for pre-B ALL therapy. Disclosures: No relevant conflicts of interest to declare.
16
Portzel, Curt A. "When The Religious Turn Litigious - Suing for America's Soul: John Whitehead, The Rutherford Institute, and Conservative Christians in the Courts. By R. Jonathan Moore. William B. Eerdmans Publishing Co.2007. Pp. ix + 215. ISBN: 0-802-84044-8." Journal of Law and Religion 24, no. 1 (2008): 345–50. http://dx.doi.org/10.1017/s0748081400002253.
Full text
17
Goncalves, Daciberg Lima, and Marek Golasinski. "On co-Moore spaces." MATHEMATICA SCANDINAVICA 83, no. 1 (September 1, 1998): 42. http://dx.doi.org/10.7146/math.scand.a-13841.
Full text
18
Wang, Zihao, Lijiao Yang, Zezhong Shan, Lu Tang, Cheng Chen, Yeqing Lan, and Wei Li. "Fabrication of magnetic cobalt‑iron composite moored on carbon derived from cigarette butts (Co Fe@CCB) for peroxymonosulfate activation to efficiently degrade Rhodamine B." Journal of Water Process Engineering 53 (July 2023): 103845. http://dx.doi.org/10.1016/j.jwpe.2023.103845.
Full text
19
Maloney, Michael F., Emrah Ilker Ozay, Katarina Blagovic, Carolyne Smith, Andrea A. Silva, Amber Martin, Sanjana Manja, et al. "Abstract 2853: Co-delivery of antigen-encoding mRNA and signal 2/3 mRNAs to PBMCs by Cell Squeeze® technology generates SQZ™ eAPCs that prime CD8+T cells in a humanized mouse model." Cancer Research 82, no. 12_Supplement (June 15, 2022): 2853. http://dx.doi.org/10.1158/1538-7445.am2022-2853.
Full textAbstract:
Abstract Antigen-specific CD8+ T cells are critical for mounting an effective immune response against tumors. Generation of antigen-specific T cells require interactions with multiple signals produced by antigen presenting cells (APCs). These signals are comprised of three components: (signal 1) the peptide-MHC complex binding to the T cell receptor, (signal 2) costimulatory molecules on the surface of APCs, and (signal 3) inflammatory cytokines binding to cognate receptors on T cells. To engineer all major cell subsets of human peripheral blood mononuclear cells (PBMCs) to become enhanced APCs (eAPCs), we used Cell Squeeze® technology to deliver multiple mRNAs encoding for non-self-antigens (signal 1), CD86 (signal 2), and/or membrane-bound cytokines (signal 3). The signal 3 molecules, membrane-bound IL-12 (mbIL-12) and membrane-bound IL-2 (mbIL-2), are chimeric proteins designed to increase the localized concentration of the cytokines at the immune synapse and limit off-target effects. Flow cytometry confirmed translation of delivered signal 2/3 mRNAs by all major subsets within PBMCs: T cells, B cells, NK cells, and monocytes. The potency of these SQZ™ eAPCs was assessed in vitro by culturing the eAPCs with antigen-specific T cells for multiple days before measuring the functionality of antigen-specific T cells via intracellular cytokine staining or ELISA. Using this approach, we demonstrate that Cell Squeeze® co-delivery of antigen mRNA and signal 2/3 mRNAs significantly enhances CD8+ T cell responses to a variety of antigens, including CMV pp65, Influenza M1, HPV16 E6, and HPV16 E7. Furthermore, we demonstrate that SQZ™ eAPCs drive significant expansion of antigen-specific CD8+ T cells in a humanized mouse model. Thus, we demonstrate that Cell Squeeze® can deliver multiple mRNAs encoding for signals 1, 2, and 3 to human PBMCs and has the potential to generate enhanced APCs that drive strong CD8+ T cell responses against multiple antigens. The versatility of this approach has the potential to enable rapid exchange of mRNA to encode for other antigens or T cell activation signals. Citation Format: Michael F. Maloney, Emrah Ilker Ozay, Katarina Blagovic, Carolyne Smith, Andrea A. Silva, Amber Martin, Sanjana Manja, Madhav Upadhyay, Lindsay J. Moore, Ryan Stagg, Henry Mack, Christine Trumpfheller, Pablo Umana, Armon Sharei, Howard Bernstein, Scott M. Loughhead. Co-delivery of antigen-encoding mRNA and signal 2/3 mRNAs to PBMCs by Cell Squeeze® technology generates SQZ™ eAPCs that prime CD8+T cells in a humanized mouse model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2853.
20
Bogaard, T. "Joseph B. Moore 1910-1989." Bulletin of the Entomological Society of America 35, no. 2 (June 1, 1989): 70. http://dx.doi.org/10.1093/besa/35.2.70a.
Full text
21
Barnscher, Stuart D., Dunja Urosev, Kevin Yin, Andrea Hernández Rojas, Sam Lawn, Vincent Fung, Jodi Wong, et al. "Abstract 2052: Screening novel format antibodies to design bispecific ADCs that address target heterogeneity." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2052. http://dx.doi.org/10.1158/1538-7445.am2024-2052.
Full textAbstract:
Abstract Addressing inter-patient and intra-tumoral target heterogeneity is a challenge for antibody drug conjugates (ADCs). The most common approach to mitigate intra-tumoral ADC target heterogeneity is to employ a bystander active payload. Once the ADC is internalized and metabolized, the payload can diffuse into tumor cells, independent of target expression. This strategy has proven effective, as evidenced by all but one of the eleven FDA-approved ADCs incorporating a bystander active payload. Nevertheless, it is important to note that in most cases there is clear evidence of an expression-response relationship, and the bystander approach does not specifically address inter-patient heterogeneity in target expression. Bispecific ADCs that can target two different tumor associated antigens (TAAs) are a promising approach to overcoming challenges associated with spatial and temporal target heterogeneity. A traditional bispecific ADC design employs a bivalent IgG where one paratope interacts with target A, and the other paratope interacts with target B. This design ensures that the molecule is maximally active when both targets A and B are present. However, this enhanced specificity approach has limitations, as it requires cellular co-expression of both targets to be effective. In contrast, a novel-format bispecific ADC targeting two different TAAs independently could increase the addressable patient population relative to a monospecific ADC. For example, a bispecific ADC with the potential for both independent and dual targeting of folate receptor alpha (FRα) and NaPi2b, established targets in ovarian cancers, could significantly expand the number of patients who could benefit relative to an ADC against either target alone. Here we describe a novel approach to the design and screening of a FRα x NaPi2b bispecific ADC library with the aim of targeting tumors that express either FRα, NaPi2b, or both targets. A library of 48 bispecific molecules was designed, employing multiple paratopes and variable antibody formats. The library comprised three valency bins, 1+1, 2+1, and 2+2, corresponding to the number of binding arms to each target. Bispecific antibodies were generated from 31 half antibodies containing Azymetric™ Het_Fc mutations. Complementary half-antibodies were combined and oxidized to generate interchain disulfide bonds, with bispecific antibody purity in the range of 90%. Antibodies and their corresponding ADCs, prepared through direct conjugation to a cytotoxic payload, were evaluated on a panel of FRα-expressing and Napi2b-expressing cancer cell lines. Key ADC parameters, including binding, internalization, and in vitro cytotoxicity, highlighted paratope combinations, valencies, and geometric formats that offer the unique potential to overcome target heterogeneity in ovarian cancer. Citation Format: Stuart D. Barnscher, Dunja Urosev, Kevin Yin, Andrea Hernández Rojas, Sam Lawn, Vincent Fung, Jodi Wong, Araba Sagoe-Wagner, Lemlem Degefie, Ali Livernois, Catrina Kim, Paul A. Moore, Jamie R. Rich. Screening novel format antibodies to design bispecific ADCs that address target heterogeneity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2052.
22
Joshu, Corinne, Keri Calkins, Jacqueline E. Rudolph, Xiaoqiang Xu, Eryka Wentz, Maneet Kaur, Filip Pirsl, Sally B. Coburn, Richard D. Moore, and Bryan Lau. "Abstract 4204: Incidence of early-onset and average-onset colon cancer among Medicaid beneficiaries with and without HIV: a cohort study." Cancer Research 83, no. 7_Supplement (April 4, 2023): 4204. http://dx.doi.org/10.1158/1538-7445.am2023-4204.
Full textAbstract:
Abstract Background: Colorectal cancer has increased among people living with HIV (PLWH). Studies have reported either no difference or lower risk of colorectal cancer incidence among PLWH as compared to the general population. We evaluated the incidence of colon cancer, both average-onset (diagnosed at 50 or older) and early-onset (diagnosed at less than 50), among a diverse population of people with and without HIV who have comparable sociodemographic factors and access to care. Methods: We obtained Medicaid Analytic eXtract (MAX) data from 2001-2015 for 14 states. We included 42,244,679 unique individuals with at least 7 months of continuous eligibility. HIV and colon cancer diagnoses were identified from inpatient and other non-drug claims. We used Cox proportional hazards regression models to assess the incidence of colon cancer, controlling for age, sex, race/ethnicity, calendar year of enrollment, state of enrollment, and number of comorbidities. Analyses were also adjusted for or stratified by age, sex, and race/ethnicity. Findings: We identified 191 colon cancer cases among 523,969 person-years among PLWH and 15,098 colon cancer cases among 63,579,078 person-years among beneficiaries without HIV. Colon cancer incidence increased with age among beneficiaries with and without HIV. Overall, HIV was modestly, inversely associated with colon cancer incidence (HR:0.84, 95%CI: 0.73, 0.98). PLWH 18-39 years old had increased hazard of colon cancer as compared to those without HIV (HR:1.67, 95%CI: 1.06, 2.65); this association was attenuated after adjustment for co-morbidities. HRs were null when early-onset colon cancer was assessed among all beneficiaries less than 50 years. PLWH had lower hazard of average-onset colon cancer compared to those without HIV (HR:0.81, 95%CI: 0.68, 0.96); this association was statistically significant among male, but not female, beneficiaries. Interpretation: Compared to beneficiaries without HIV, PLWH had a lower risk of average-onset colon cancer. PLWH had higher incidence of early-onset colon cancer, but this difference was attenuated after adjustment for comorbid conditions. Citation Format: Corinne Joshu, Keri Calkins, Jacqueline E. Rudolph, Xiaoqiang Xu, Eryka Wentz, Maneet Kaur, Filip Pirsl, Sally B. Coburn, Richard D. Moore, Bryan Lau. Incidence of early-onset and average-onset colon cancer among Medicaid beneficiaries with and without HIV: a cohort study. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4204.
23
De Jager, Nathan R., and John Pastor. "Effects of moose Alces alces population density and site productivity on the canopy geometries of birch Betula pubescens and B. pendula and Scots pine Pinus sylvestris." Wildlife Biology 14, no. 2 (June 2008): 251–62. http://dx.doi.org/10.2981/0909-6396(2008)14[251:eomaap]2.0.co;2.
Full text
24
HUANG, SI-YAO, ANTON V. VOLYNKIN, KAREL ČERNÝ, MIN WANG, and XIAO-LING FAN. "Contribution to the knowledge on the genus Barsine Walker, 1854 from mainland China and Indochina, with description of a new species (Lepidoptera, Erebidae, Arctiinae, Lithosiini)." Zootaxa 4711, no. 3 (December 17, 2019): 495–516. http://dx.doi.org/10.11646/zootaxa.4711.3.4.
Full textAbstract:
A new species of the genus Barsine, viz. Barsine fangchenglaiae Huang, Volynkin, Černý & Wang sp. nov. from SW China, N Thailand and N Vietnam is described. The following six taxa are confirmed as new records to China: B. pretiosa Moore, 1879, B. defecta defecta Walker, 1854, B. gratissima (de Joannis, 1930), B. flammealis Moore, 1878, B. mactans Butler, 1877 and Barsine vinhphucensis Spitsyn et al., 2018. The new synonymy is established: Barsine pretiosa Moore, 1879 = Barsine pseudomactans Volynkin & Černý, 2016, syn. nov. Adults and genitalia of all species aforementioned are illustrated.
25
Doman, Ryszard. "Moore G-Spaces Which are not Co-Hopf G-Spaces." Canadian Mathematical Bulletin 32, no. 3 (September 1, 1989): 365–68. http://dx.doi.org/10.4153/cmb-1989-053-9.
Full textAbstract:
AbstractLet G be a finite group. By a Moore G-space we mean a G-space X such that for each subgroup H of G the fixed point space XH is a simply connected Moore space of type (MH,n), where MH is an abelian group depending on H, and n is a fixed integer. By a co-Hopf G-space we mean a G-space with a G-equivariant comultiplication. In this note it is shown that, in contrast to the non-equivariant case, there exist Moore G-spaces which are not co-Hopf G-spaces.
26
Arkowitz, Martin, and Marek Golasiński. "Co-H-structures on equivariant Moore spaces." Fundamenta Mathematicae 146, no. 1 (1994): 59–67. http://dx.doi.org/10.4064/fm-146-1-59-67.
Full text
27
Volynkin, Anton V., Karel Černý, and Si-Yao Huang. "A review of the Barsine perpallida-B. yuennanensis species-group, with descriptions of six new species (Lepidoptera: Erebidae: Arctiinae)." Acta Entomologica Musei Nationalis Pragae 59, no. 1 (October 1, 2019): 273–93. http://dx.doi.org/10.2478/aemnp-2019-0022.
Full textAbstract:
Abstract The Barsine perpallida-B. yuennanensis species-group is reviewed. Six new species, B. biformis Volynkin & Černý, sp. nov. (North Thailand and North Vietnam), B. laszloi Volynkin & Černý, sp. nov. (Nepal), B. hausmanni Volynkin & Černý, sp. nov. (North Thailand), B. andromeda Volynkin, Černý & Huang, sp. nov. (China: Shaanxi and Sichuan), B. eurydice Volynkin & Černý, sp. nov. (North Vietnam), and B. dao Volynkin, Černý & Huang, sp. nov. (North Vietnam and China: Yunnan), are described. All species treated are subdivided into five subgroups: B. biformis, B. perpallida, B. flavicollis, B. hausmanni, and B. yuennanensis subgroups. Four new combinations are established: Barsine hololeuca (Hampson, 1895), comb. nov., B. ruficollis (Fang, 1991), comb. nov., Barsine nigrovena (Fang, 2000), comb. nov. (all three from Miltochrista Hübner, [1819]), and B. flavicollis (Moore, 1878), comb. nov. (from Mahavira Moore, 1878). A lectotype for Mahavira flavicollis Moore, 1878 is designated. One new synonymy is established: B. perpallida (Hampson, 1900) = Diacrisia porthesioides Rothschild, 1910, syn. nov. Adults, male and female genitalia of all species are illustrated.
28
KLAPPER, G., T. T. UYENO, D. K. ARMSTRONG, and P. G. TELFORD. "CONODONTS OF THE WILLIAMS ISLAND AND LONG RAPIDS FORMATIONS (UPPER DEVONIAN, FRASNIAN-FAMENNIAN) OF THE ONAKAWANA B DRILLHOLE, MOOSE RIVER BASIN, NORTHERN ONTARIO, WITH A REVISION OF LOWER FAMENNIAN SPECIES." Journal of Paleontology 78, no. 2 (February 2004): 371–87. http://dx.doi.org/10.1666/0022-3360(2004)078<0371:cotwia>2.0.co;2.
Full text
29
Castro-Gonzalez, Nieves, and Robert Hartwig. "Perturbation results and the forward order law for the Moore-Penrose inverse of a product." Electronic Journal of Linear Algebra 34 (February 21, 2018): 514–25. http://dx.doi.org/10.13001/1081-3810.3365.
Full textAbstract:
New expressions are given for the Moore-Penrose inverse of a product $AB$ of two complex matrices. Furthermore, an expression for $(AB)\dg - B\dg A\dg$ for the case where $A$ or $B$ is of full rank is provided. Necessary and sufficient conditions for the forward order law for the Moore-Penrose inverse of a product to hold are established. The perturbation results presented in this paper are applied to characterize some mixed-typed reverse order laws for the Moore-Penrose inverse, as well as the reverse order law.
30
Kanyandekwe, Joël, Matthias Bauer, Tanguy Marion, Lazhar Saidi, Jean-Baptiste Pin, Jeremie Bisserier, Jérôme Richy, et al. "Very Low Temperature Tensile and Selective Si:P Epitaxy for Advanced CMOS Devices." ECS Meeting Abstracts MA2022-02, no. 32 (October 9, 2022): 1190. http://dx.doi.org/10.1149/ma2022-02321190mtgabs.
Full textAbstract:
Nowadays, “more Moore” and “more than Moore” device architectures are becoming more and more complex. In CEA-Leti, we work on the “CoolCubeTM” 3D sequential integration which is based on the stacking of FDSOI devices [1]. We present solutions, at T<500°C, for the integration of SiP Raised Sources & Drains (RSD) in the upper devices without degrading the electrical performances of the bottom ones. We also target a lowering of the RSD resistance and an increase of the electron mobility in the channel of NMOS devices thanks to tensile strain [2]. Such a know-how will be useful to minimize the contact resistance and fabricate other types of devices such as FINFETs or h-GAA (e.g. nano-sheet devices) with Si (110) surfaces. Experiments were carried out in an Applied Materials epitaxy reactor featuring (i) liquid precursor delivery, together with H2, N2 or He carrier gas capability, enabling the use of Cl2; (ii) “High Precision Temperature Control (HPTC)”, allowing excellent LT control and enabling flexible rotation speeds; (iii) “precision flow distribution PFD-III”, enhancing uniformity performances. Selective Epitaxial Growth (SEG) is usually obtained with “co-flow” processes at rather high temperatures (>600°C). Chlorinated precursors (SiH2Cl2 (+ GeH4) + HCl, typically) are then sent simultaneously into the growth chamber. At LT (<500C°C), HCl cannot decompose, however. To overcome those limitations, we used a Cyclic Deposition Etch (CDE) strategy, with non-selective depositions followed by selective chemical vapor etches, to obtain SiP SEG. This strategy allowed us to obtain high quality films, as shown in Fig.1. The Omega-2Theta scans around the (004) X-Ray Diffraction order for tensile SiP (t-SiP) layers grown at T < 500°C with different Phosphorus concentrations were indeed typical of monocrystalline layers, with well-defined and intense peaks together with numerous thickness fringes. The substitutional P contents in those ~ 60 nm thick t-SiP layers were in the 1.02% - 5.42% range. The good layer uniformity in terms of thickness and P content, over a 300mm wafer radius, is shown in figure Fig.2. These layers grown at T <500°C were smooth, as shown in Fig.3, with a 0.21 nm Root Mean Square (RMS) roughness for a 60nm thick Si:P layer, i.e. a value close to the typical RMS roughness for t-SiP layers grown at high temperature with a chlorinated chemistry. The electrical resistivity in various t-SiP layers is plotted in Fig.4 as function of the substitutional phosphorus concentration and for various growth temperatures in the 450°C – 525°C range. Reducing the temperature by 75°C halved the electrical resistivity. We were able to achieve a resistivity as low as 0.21 mOhm.cm for a t-SiP layer with 5.8% of P grown at 450°C. We then evaluated, at first on tests structures without gates, our process selectivity. A top view Scanning Electron Microscopy image of a t-SiP layer grown non-selectively, with numerous amorphous SiP nuclei on SiO2, is shown in Fig 5.a. After some careful optimization, we succeeded in having fully selective processes versus SiO2, as shown in Fig 5.b. We then tested such optimized processes on low density FD-SOI devices with 28 nm design rules. A top-view SEM image of transistors after such a growth is shown in Fig.6. The growth selectivity was excellent, with nitride spacers and hard masks as well as isolations free of a-SiP nuclei for 31 nm of t-SiP with 4.5% of P deposited in the Sources/Drains. The surface was smooth, with a RMS roughness as low as 0.30nm on active areas, as shown in Fig.7. Thanks to High Resolution Reciprocal Space Maps (HR-RSM), we measured a Phosphorus concentration of 4.5% for that SiP layer grown on SOI. The very high quality of that epitaxy layer, with well-defined thickness fringes, is obvious in Fig.8. Cross-sectional Transmission Electron Microscopy (TEM) images such as the one shown in Fig. 9 enabled us to confirm, at the nanoscale, the excellent quality of such layers in RSDs. To sum up, we were able to develop a tensile Si:P process which was shown to be selective, at a temperature lower than 500°C, against SiO2 and SiN. Such t-SiP layers were successfully integrated in the Sources/Drains regions of FD-SOI 28nm devices. The very low material resistivity and the high phosphorus content should yield, notably because of tensile strain, performant NMOS devices in the near future. [1] C. Fenouillet-Beranger et al., IEEE TED 68, 3142-3148 (2021) [2] V. Chan et al., IEEE 2005 Custom Integrated Circuits Conference 2005, pp. 667-674 Figure 1
31
DAMM, TOBIAS, and HARALD K. WIMMER. "A CANCELLATION PROPERTY OF THE MOORE–PENROSE INVERSE OF TRIPLE PRODUCTS." Journal of the Australian Mathematical Society 86, no. 1 (February 2009): 33–44. http://dx.doi.org/10.1017/s144678870800044x.
Full textAbstract:
AbstractWe study the matrix equation C(BXC)†B=X†, where X† denotes the Moore–Penrose inverse. We derive conditions for the consistency of the equation and express all its solutions using singular vectors of B and C. Applications to compliance matrices in molecular dynamics, to mixed reverse-order laws of generalized inverses and to weighted Moore–Penrose inverses are given.
32
Furfari, F. A. "First IAS President - Robert B. Moore, 1918-2003." IEEE Industry Applications Magazine 10, no. 2 (March 2004): 8. http://dx.doi.org/10.1109/mia.2004.1270794.
Full text
33
Xu, Sanzhang, and Jianlong Chen. "The Moore-Penrose inverse in rings with involution." Filomat 33, no. 18 (2019): 5791–802. http://dx.doi.org/10.2298/fil1918791x.
Full textAbstract:
Let R be a unital ring with involution. In this paper, we first show that for an element a 2 R, a is Moore-Penrose invertible if and only if a is well-supported if and only if a is co-supported. Moreover, several new necessary and sufficient conditions for the existence of the Moore-Penrose inverse of an element in a ring R are obtained. In addition, the formulae of the Moore-Penrose inverse of an element in a ring are presented.
34
Stelzer, Manfred. "On certain co–H spaces related to Moore spaces." Transactions of the American Mathematical Society 354, no. 8 (March 29, 2002): 3085–93. http://dx.doi.org/10.1090/s0002-9947-02-02995-1.
Full text
35
JOSHI, RAHUL, NAVNEET SINGH, and ANTON V. VOLYNKIN. "New data on the genus Barsine Walker, 1854 from India, with description of a new species (Lepidoptera: Erebidae: Arctiinae: Lithosiini)." Zootaxa 4425, no. 3 (May 31, 2018): 456. http://dx.doi.org/10.11646/zootaxa.4425.3.2.
Full textAbstract:
A new species, Barsine pseudoradians Joshi, Singh & Volynkin sp. nov. is described from North East India (Mizoram, Assam and Meghalaya) and Nepal. The new species belongs to the Barsine prominens (Moore) species-group and is compared with B. radians (Moore, 1878), B. pluma Černy, 2009, B. syntypica Swinhoe, 1906 and B. maculifasciata (Hampson, 1894). Barsine callida (Fang, 1991) is reported for the first time from India. Its comparison with the related Barsine mesortha (Hampson, 1898) is given. Two new combinations are established: Barsine callida (Fang, 1991), comb. nov. and Barsine germana (Rothschild, 1913), comb. nov. Adults, male and female genitalia of all the reviewed species are illustrated.
36
Bulundwe, K. Luc. "La clôture comme ouverture. Analyse mémorielle du rôle de 2 Timothée dans le corpus paulinien." Études théologiques et religieuses Tome 98, no. 2 (July 18, 2023): 265–78. http://dx.doi.org/10.3917/etr.982.0265.
Full textAbstract:
Rédigée comme un discours d’adieu, la deuxième épître à Timothée (2 Tm) s’attribue un rôle de clôture dans la biographie de l’apôtre Paul. Comment cette prétention – déguisée ou non – se traduit-elle du point de vue narratif ? Ou, pour le dire autrement, quel rôle 2 Tm endosse-t-elle au sein du corpus paulinien ? Cette question conduit l’argumentaire de la présente thèse de doctorat. Au prisme des approches sociales de la mémoire, cette étude heuristique démontre que le genre littéraire et le contenu de la lettre façonnent une clé herméneutique pour lire et diffuser, au moins, les sept lettres dites proto-pauliniennes (Rm, 1 et 2 Co, Ga, Ph, 1 Th, Phm) et Colossiens comme « héritage essentiel » (B. Schwartz) de l’apôtre Paul. Sa principale originalité réside dans la considération spécifique de 2 Tm au sein d’une collection paulinienne et non uniquement dans le corpus dit des Pastorales (1 et 2 Tm, Tt). La thèse s’organise en trois parties : 1) les jalons historiques et méthodologiques ; 2) l’analyse mémorielle de 2 Tm ; 3) une enquête sur trois « lieux de mémoire » (P. Nora) pauliniens en 2 Tm : les personnages, les lieux géographiques et les lettres de Paul.
37
Arkowitz, Martin, and Marek Golasinski. "Co-H-Structures on Moore Spaces of Type (G, 2)." Canadian Journal of Mathematics 46, no. 4 (August 1, 1994): 673–86. http://dx.doi.org/10.4153/cjm-1994-037-0.
Full textAbstract:
AbstractWe consider the set (of homotopy classes) of co-H-structures on a Moore space M(G,n), where G is an abelian group and n is an integer ≥ 2. It is shown that for n > 2 the set has one element and for n = 2 the set is in one-one correspondence with Ext(G, G ⊗ G). We make a detailed investigation of the co-H-structures on M(G, 2) in the case G = ℤm, the integers mod m. We give a specific indexing of the co-H-structures on M(ℤm, 2) and of the homotopy classes of maps from M(ℤm, 2) to M(ℤn, 2) by means of certain standard homotopy elements. In terms of this indexing we completely determine the co-H-maps from M{ℤm, 2) to M(ℤn, 2) for each co-H-structure on M(ℤm, 2) and on M(ℤn, 2). This enables us to describe the action of the group of homotopy equivalences of M(ℤn, 2) on the set of co-H-structures of M(ℤm, 2). We prove that the action is transitive. From this it follows that if m is odd, all co-H-structures on M(ℤm, 2) are associative and commutative, and if m is even, all co-H-structures on M(ℤm, 2) are associative and non-commutative.
38
Mahmood, Rafat, Jan Philipp Hofmann, Wolfram Jaegermann, Michael Reindl, and Natascha Weidler. "(Digital Presentation) Investigation of Reversal Tolerant Anode Catalysts Ageing during Start-up/Shut-Down Events on a PEM Fuel Cell." ECS Meeting Abstracts MA2022-01, no. 35 (July 7, 2022): 1467. http://dx.doi.org/10.1149/ma2022-01351467mtgabs.
Full textAbstract:
Durability of automotive polymer electrolyte membrane fuel cells (PEMFC) strongly depends on transient operating conditions such as start-up/shut-down (SUSD). During SUSD events, the hydrogen atmosphere at the anode compartment can be replaced by air (shut-down) and vice-versa (start-up), which can lead to the formation of a hydrogen and air interface in the anode side resulting in a lack of hydrogen supply situation. In the event of a hydrogen-starved situation, the carbon-based support material can be oxidized to supply the necessary electron to complete the load circuit resulting in cell reversal mode, when the anode potential rises above 1.0 V (vs. reversible hydrogen electrode). Such events can damage the anode catalyst layer and reduce the fuel cell lifetime. One of the many ways to mitigate the cell reversal condition is to incorporate reversal tolerant anode catalysts with hydrogen oxidation reaction (HOR) catalysts to facilitate the oxygen evolution reaction (OER) over the carbon oxidation reaction (COR) 1. IrO2 is commonly used as a reversal tolerant anode catalyst because of its high activity and stability under acidic conditions. Several studies have shown the effectiveness of IrO2 as an OER catalyst to alleviate cell reversal events 2. Recent studies have shown that IrO2 can be reduced to metallic Ir under highly reducing hydrogen atmosphere in PEM fuel cell anodes 3. While IrO2 serves its purpose as an OER catalyst, the stability of IrO2 under the transient operation of a PEM fuel cell, such as SUSD, and the impact on overall catalyst durability as well as cell performance are still unresolved. In this work, we have developed an accelerated stress test (AST) which allows to simulate the transient operation during SUSD analogous to real operation of a PEM fuel cell by an active gas switch from hydrogen to air at the anode side. We discuss the consequences of this transient SUSD condition on the anode catalyst as well as cathode catalyst layer characterized by cyclic voltammetry, where hydrogen under potential deposition (Hupd) features show the change in effective catalyst surface area. The impact on reversal tolerance performance of the IrO2 OER catalyst has been determined by the extended exposure to reversal conditions. Post-characterization surface analysis by X-ray photoelectron spectroscopy (XPS) reveals the change of chemical state of the materials on both anode and cathode catalyst layers resulting from active gas switching at the anode. Finally, the overall PEM fuel cell performance and durability are discussed. References Hong, B. K., Mandal, P., Oh, J.-G. & Litster, S. On the impact of water activity on reversal tolerant fuel cell anode performance and durability. Journal of Power Sources 328, 280–288 (2016). Moore, C. E., Eastcott, J., Cimenti, M., Kremliakova, N. & Gyenge, E. L. Novel methodology for ex situ characterization of iridium oxide catalysts in voltage reversal tolerant proton exchange membrane fuel cell anodes. Journal of Power Sources 417, 53–60 (2019). Fathi Tovini, M. et al. Degradation Mechanism of an IrO2 Anode Co-Catalyst for Cell Voltage Reversal Mitigation under Transient Operation Conditions of a PEM Fuel Cell. J. Electrochem. Soc. 168, 064521 (2021).
39
Dimou, Anastasios, Raymond M. Moore, Caitlin Ward, Alexey Leontovich, Ruifeng Guo, Chen Wang, Shankar Suman, et al. "Abstract 2905: Spatial analysis of neuropilin 2 expression in the microenvironment of melanoma." Cancer Research 84, no. 6_Supplement (March 22, 2024): 2905. http://dx.doi.org/10.1158/1538-7445.am2024-2905.
Full textAbstract:
Abstract Background: Neuropilin 2 (NRP2) is a co-receptor that enhances signaling of growth factor and cytokine receptors and is expressed in tumor and microenvironment (TME) cells in melanoma and other tumors. Neuropilin 2 expression in tumor cells is associated with more aggressive tumors. Expression in tumor associated macrophages enhances efferocytosis and immunologically silent tumor cell death. Methods: Whole excisional lymph node biopsies were obtained from 10 treatment naïve patients with metastatic cutaneous melanoma who subsequently received anti-PD1 treatment. A single 5mm formalin-fixed paraffin embedded tissue section was used to assess a panel of 39 analytes by cyclic multiplex immunofluorescence (MxIF). Fields of view (~1mm2, n=288) were selected from pathologist-annotated regions of the tumor core, tumor-immune interface and adjacent lymphoid tissue. Pixel-based single cell segmentation and a supervised classifier approach was applied to resolve 12 distinct tumor, stromal and immune cell phenotypes and functional states (NRP2 positive or negative) in 1.5 million cells. Results: Tumor recurrence was observed in 6 patients (relapsed), whereas 4 patients were recurrence-free (non-relapsed) during follow up. Among the different cell types, NRP2 expression was more frequent in macrophages (44%), tumor cells (40%), dendritic cells (40%), followed by Tregs (31%) and T helper cells (29%), and less frequent in neutrophils (24%), cytotoxic T cells (23%) and B cells (15%). In colocalization permutation analysis, NRP2 expressing macrophages clustered away from tumor cells in non-relapsed patients while a random spatial distribution of NRP2 expressing macrophages with respect to tumor cells was observed in relapsed patients. In comparing the odds of tumor cell interactions with NRP2-expressing macrophages to those with NRP2 non-expressing macrophages, we found in the tumor:stromal interface (10% tumor cells) that cells from both non-relapsed and relapsed patients were more likely to interact with NRP2 non-expressing macrophages (OR = 0.73, 95% CI = [0.71, 0.75] and OR = 0.56, 95% CI = [0.55, 0.58] for non-relapsed and relapsed patients, respectively). However, in the tumor core (90% tumor cells), tumor cells from relapsed patients had significantly higher odds of interacting with NRP2 expressing macrophages, (OR = 1.15, 95% CI = [1.12, 1.18]), and this was not seen for non-relapsed patients (OR = 0.68, 95% CI = [0.66, 0.71]). In FOVs dominated by tumor cells (75% tumor), tumor cells from relapsed patients had 4.97 times the odds of expressing NRP2 compared to tumor cells from non-relapsed patients (95% CI = [2.23, 11.09], p = 0.0001). Conclusions: These spatial analytics suggest complex interactions among NRP2 expression in tumor and TME of melanoma determining risk for relapse with anti-PD1 treatment. Citation Format: Anastasios Dimou, Raymond M. Moore, Caitlin Ward, Alexey Leontovich, Ruifeng Guo, Chen Wang, Shankar Suman, Betty Dicke, Jill M. Schimke, Noah A. Stueven, Chathu A. Atherton, Wendy Nevala, Svetomir N. Markovic. Spatial analysis of neuropilin 2 expression in the microenvironment of melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2905.
40
Gritsans, Armands, and Felix Sadyrbaev. "Extension of the example by Moore-Nehari." Tatra Mountains Mathematical Publications 63, no. 1 (June 1, 2015): 115–27. http://dx.doi.org/10.1515/tmmp-2015-0024.
Full textAbstract:
Abstract R. Moore and Z. Nehari developed the variational theory for superlinear boundary value problems of the form x'' = p(t) |x|2εx, x(a) = 0 = x(b), where ε > 0 and p(t) is a positive continuous function. They constructed simple example of the equation considered in the interval [0, b] so that the problem had three positive solutions. We show that this example can be extended so that the respective BVP has infinitely many groups of solutions with a presribed number of zeros.
41
Yang, Zhaofu, Misbah Ullah, Jean-François Landry, Scott E. Miller, Margaret E. Rosati, and Yalin Zhang. "Reassessment of the moth genus Bacotoma, with a new species from Hainan Island (Lepidoptera: Crambidae: Spilomelinae)." Insect Systematics & Evolution 51, no. 3 (May 22, 2020): 384–407. http://dx.doi.org/10.1163/1876312x-00002205.
Full textAbstract:
Bacotoma Moore, 1885 is reviewed including the description of a new species from Hainan Island, B. hainanensis sp. nov., based on an analysis that combined morphology and mitochondrial DNA. The following taxonomic changes are proposed: Platamonina Shaffer & Munroe, 2007, syn. nov. is synonymized with Bacotoma and ten species are included: B. ampliatalis (Lederer, 1863) comb. nov., B. binotalis (Warren, 1896) comb. nov., B. camillusalis (Walker, 1859), B. cuprealis (Moore, 1877) comb. nov., B. hainanensis sp. nov., B. illatalis (Walker, 1866), B. oggalis (Swinhoe, 1906) comb. nov., B. poecilura (Hering, 1903) comb. nov., B. ptochura (Meyrick, 1894) comb. nov., and B. violata (Fabricius, 1787). Syngamia albiceps Hampson, 1912 syn. nov. is confirmed to be a synonym of Bacotoma binotalis, and Platamonia medinalis Snellen, 1900 syn. nov. is synonymized with Bacotoma illatalis. A key to species examined is also provided based on external morphology and male genitalia.
42
CARRERA-MARTÍNEZ, ROBERTO, DANIEL JONES, SEAN D. SCHOVILLE, BRUCE A. SNYDER, and MAC A. JR CALLAHAM. "Two new species of Bimastos (Oligochaeta, Lumbricidae) from the Southern Appalachian Mountains, North America." Zootaxa 5052, no. 3 (October 15, 2021): 395–405. http://dx.doi.org/10.11646/zootaxa.5052.3.5.
Full textAbstract:
Two new species of Bimastos Moore are described based on morphological and molecular data. Bimastos nanae n. sp. resembles B. lawrenceae Fender, B. zeteki (Smith and Gittins) and B. welchi (Smith). Bimastos nanae n. sp. differs from these species in the position of the clitellum, size and number and position of thickened septa. Bimastos magnum n. sp. is similar to B. schwerti Csuzdi & Chang and B. palustris Moore in having a fully annular clitellum and male pores on huge porophores. Bimastos magnum n. sp. differs from both species by having a more posterior position of the clitellum (in xxiv-xxxiii, xxxiv) and larger body size. With the description of these new species, the number of Bimastos species is raised to 14.
43
Lehnen, Leila. "Planet Earth Strikes Back: Landscapes of Toxicity in Latin American Fiction." Journal of Foreign Languages and Cultures 5, no. 2 (December 28, 2021): 022–32. http://dx.doi.org/10.53397/hunnu.jflc.202102003.
Full textAbstract:
This essay discusses how contemporary Latin American literature (Argentina, Brazil, and Colombia) employs the discourse of toxicity—condensed in the metaphor of bio-engineering and mutation—to process and interrogate what Jason Moore has called the “Capitolecene.” Moore proposes to understand the “accumulation of capital, the pursuit of power, and the co-production of nature in dialectical unity.” This essay considers how the co-production of nature, impelled by greed (a recurring allegory of capitalism) goes terribly wrong by generating toxic biomes. As such, these texts function as ecocritical allegories of the Capitolecene (specifically in its iteration as biocapitalism) and its human and environmental consequences.
44
Bingma, Vangile. "Elena Moore (Ed.). Generation, Gender and Negotiating Custom in South Africa." Journal of Comparative Family Studies 54, no. 3 (March 1, 2024): 298–301. http://dx.doi.org/10.3138/jcfs.54.3.06.
Full text
45
Veretennikov, Andrey A. "McTaggart: Reality in Idealism." Epistemology & Philosophy of Science 56, no. 2 (2019): 203–10. http://dx.doi.org/10.5840/eps201956238.
Full textAbstract:
Article is dedicated to the description and analysis of metaphilosophical and scientific contexts of the McTaggart paper ‘The Unreality of Time’ (1908) and drawing connections to the ‘analytical’ style of his pupils – B. Russell and G.E. Moore. Main line of argument against the reality of time is presented and analyzed. By the positive relation of McTaggart to the work on ethics by G.E. Moore and negative – to philosophical implications of the special theory of relativity author shows the movement for the autonomy of philosophy or ‘antipsychologism’. Question of a different understanding of the term ‘reality’ in Moore and McTaggart is posed and resolved.
46
Volynkin, Anton V., and Karel Černý. "A REVIEW OF THE BARSINE FLAMMEALIS SPECIES-COMPLEX WITH DESCRIPTION OF A NEW SPECIES FROM HIMALAYA (LEPIDOPTERA, EREBIDAE, ARCTIINAE)." Biological Bulletin of Bogdan Chmelnitskiy Melitopol State Pedagogical University 6, no. 3 (December 19, 2016): 303–10. http://dx.doi.org/10.15421/201699.
Full textAbstract:
<p>The paper contains a review of the <em>Barsine flammealis </em>species-complex. The status of <em>Barsine pretiosa </em>Moore, 1879 is revised, diagnoses for <em>B. flammealis </em>Moore, 1878 and <em>B. pretiosa </em>are given. A new species, <em>Barsine pseudomactans </em>Volynkin & Černý, sp. nov. is described from Himalaya (eastern India, Bhutan and Nepal). Adults, male and female genitalia of all species mentioned are illustrated.</p>
47
Rostky, George. "The IC's Surprising Birth." Mechanical Engineering 122, no. 06 (June 1, 2000): 68–73. http://dx.doi.org/10.1115/1.2000-jun-5.
Full textAbstract:
This article reviews the origin and costs of integrated circuits in the semiconductor industry. Sometimes, a significant integrated circuit achievement might not receive history’s recognition because it simply did not work well. The market might politely applaud a new development, but if another came along that was considerably cheaper, it would be seized hungrily. It would become the market leader and later in history's eyes, might appear to have been first. Jean Hoerni from Fairchild Semiconductor, in Mountain View, CA, developed a new transistor with all parts on one plane. He made connections through an insulating and protecting layer of oxide. Fairchild formed two design teams, one under co-founder Cordon Moore, to develop NPN, and one under co-founder Hoerni, who was working for Moore, to develop PNPs. Both projects were successful—Moore’s NPN, the 2N967, the first high-performance silicon transistor, and Hoerni’s PNP, the 2Nl132. But the NPN was easier to make at first, so Moore chose that one for IBM. Today, ICs house millions of transistors at costs of a fraction of a mil per transistor.
48
Turner, Nicolas C., Sherene Loi, Heather M. Moore, Ching-Wei Chang, Jennifer Eng-Wong, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Komal L. Jhaveri, and Elgene Lim. "Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC)." Cancer Research 82, no. 4_Supplement (February 15, 2022): PD13–07—PD13–07. http://dx.doi.org/10.1158/1538-7445.sabcs21-pd13-07.
Full textAbstract:
Abstract Background A mainstay of ER+ BC treatment is to target ER activity and/or estrogen synthesis; however, during or after endocrine therapy (ET), many patients either relapse or develop resistance to such treatments due to several mechanisms, including ESR1 mutations which can be drivers of estrogen-independent transcription and proliferation. The majority of tumors remain dependent on ER signaling, and it is possible that patients will be responsive to second- or third-line ET after they have progressed on previous therapies. The highly potent, nonsteroidal oral selective ER antagonist and degrader G achieves robust ER occupancy and is active in patients with either ESR1-wildtype or -mutant tumors and in patients who had previously been treated with ET. G was well tolerated as a single agent and in combination with palbo, with antitumor activity shown in the nonrandomized, open-label, dose-escalation and -expansion, phase Ia/b GO39932 study (NCT03332797). We present updated activity and biomarker analyses in patients treated with 30 mg G monotherapy and those treated with 100 mg G + 125 mg palbo ± luteinizing hormone-releasing hormone (LHRH) agonists (clinical cutoff: Apr 16, 2021); 30 mg has since been selected as the dose in both the single agent and combination settings. Methods Eligible patients had ≤2 prior therapies for LA/mBC, disease recurrence, or progression while on adjuvant ET for ≥24 months and/or ET for LA/mBC, and tumor response or stable disease ≥6 months. All were postmenopausal (premenopausal women were allowed co-administered LHRH agonists with 100 mg G). Oral G was given daily on Days (D)1-28 of each 28-day cycle (C); 125 mg palbo, on a 21-day on/7-day off schedule. Modulation of ER signaling and proliferation of paired pre- and on-treatment (C2D8) tumor biopsies were assessed with immunohistochemistry for ER, progesterone receptor (PgR), and the proliferation marker Ki67, as well as with gene expression analysis of a predefined set of 38 ER target genes using the Illumina TruSeq RNA Access method. Plasma samples collected pre- and on-treatment (C1D15 and/or C2D1) were assessed for circulating tumor (ct)DNA using a digital PCR BEAMing assay detecting a total of 22 mutations across ESR1, AKT1, and PIK3CA. Results Objective response rates in patients with measurable disease at baseline were 20.0% in the 30 mg G group (6/30 patients) and 47.7% in the 100 mg G + palbo ± LHRH (combination) group (21/44). Clinical benefit rates were 55.0% (22/40 patients) and 81.3% (39/48), respectively. Overall, 21 pre- and on-treatment-paired tumor biopsies were collected in the 30 mg (n=13) and combination (n=8) groups. Consistent downregulation of ER, PgR, Ki67, and ER pathway activity was observed at C2D8, regardless of clinical benefit or baseline ESR1 mutation, demonstrating consistent on-target activity of G. Stronger Ki67, ER, and PgR suppression was seen with the addition of palbo to G. Of the 36 patients across both cohorts with a detectable ctDNA baseline ESR1 mutation, 16 had >1 baseline ESR1 mutation. Of the eight unique ESR1 mutations detected, none showed an association with response. At C2D1, 34 patients had a decrease in ESR1 ctDNA levels from baseline, of which 27 became undetectable for ESR1 ctDNA. Early changes in PIK3CA and AKT1 ctDNA levels, but not ESR1, trended with response. Conclusions Encouraging clinical activity was observed with single agent G at 30 mg and with G at 100 mg in combination with palbo. Biomarker analyses demonstrated consistent biologic activity of G, and largely consistent decreases of ESR1 ctDNA levels. Further updated activity and biomarker data, including PAM50 subtype classifications, will be presented. Citation Format: Nicolas C Turner, Sherene Loi, Heather M Moore, Ching-Wei Chang, Jennifer Eng-Wong, Aditya Bardia, Valentina Boni, Joohyuk Sohn, Komal L Jhaveri, Elgene Lim. Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2- LA/mBC) [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD13-07.
49
Gibson, David J. "Methods in Plant Ecology P. D. Moore S. B. Chapman." American Biology Teacher 50, no. 6 (September 1988): 391–94. http://dx.doi.org/10.2307/4448773.
Full text
50
Lewis, Linden. "Richard B. Moore: the Making of a Caribbean Organic Intellectual." Journal of Black Studies 25, no. 5 (May 1995): 589–609. http://dx.doi.org/10.1177/002193479502500505.
Full text